Atomoxetine

Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na+ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].

Product Specifications

CAS Number

[83015-26-3]

Product Name Alternative

Tomoxetine; (R) -Tomoxetine

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Serotonin Transporter; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/atomoxetine.html

Solubility

10 mM in DMSO

Smiles

CC(C=CC=C1)=C1O[C@@H](C2=CC=CC=C2)CCNC

Molecular Formula

C17H21NO

Molecular Weight

255.35

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. |[2]Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489.|[3]Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27 (5) :699-711.